39 results about "Zolmitriptan" patented technology

A method of treatment or prevention of headache, migraine or cluster headaches, which method comprises co-administration of a therapeutically effective amount of the compound 1-[N<2>-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]-carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine[BIBN4096BS] or a physiologically acceptable salt thereof and a therapeutically effective amount of a second active antimigraine drug, particularly sumatriptan, zolmitriptan or dihydroergotamin or a physiologically acceptable salt thereof, as well as to the corresponding pharmaceutical compositions and the preparation thereof.

The present invention relates to a process for the treatment or prevention of indications which are selected from among the group comprising headaches, migraine and cluster headaches, this process comprising the joint administration of a therapeutically effective amount of a selected CGRP antagonist (A), a physiologically acceptable salt thereof or a hydrate of the salt and a therapeutically effective amount of a second or third active anti-migraine medicament (B), particularly sumatriptan, zolmitriptan or dihydroergotamine or a physiologically acceptable salt thereof, and to the corresponding pharmaceutical compositions and the preparation thereof.

The invention provides a zolmitriptan sublingual tablet, which is characterized in that it contains the main drug zolmitriptan, a disintegrating agent and a filler. In every 1000 sublingual tablets, the content of zolmitriptan is 1 -50g, the content of disintegrating agent is 2-20g, the content of filler is 40-200g; it also contains 0-20g of corrective agent, 10-60g of binder and 0.5-5g of lubricant. The present invention utilizes the characteristics of non-keratinized sublingual mucosa, rich capillaries, and fast blood flow, aiming at the absorption of zolmitriptan ordinary tablets through the gastrointestinal tract, slow onset of action, first-pass effect, and low bioavailability. The deficiencies of advanced prior art, zolmitriptan is made into sublingual tablet, can make it absorb through sublingual mucosa, directly enter blood circulation through jugular vein and superior vena cava, take effect rapidly; Avoid oral administration The first-pass effect improves bioavailability and ensures curative effect. Moreover, water is not needed when taking the medicine, and it is placed under the tongue to contain it, so it is convenient to take and has a good taste. With the characteristics of rapid onset of action, convenient administration and high bioavailability, it can provide patients with a new treatment option and fill the gap in the market.

A process for preparing zolmitriptan, proceeding through the intermediate Ethyl-3-[2-(1,3-dioxo-2,3-dihydro-1H-2-isoindoleyl)ethyl]-5-[(4S)-2-oxo-1,3-oxazolan-4-ylmethyl]-1H-2-indole carboxylate.

The chiral chromatographic fixed phase stuffing of vancomycin phenylisocyanate is prepared through bonding vancomycin as glycopeptide macrocyclic antiseptic chemical onto silicon gel carrier, and the subsequent derivation of phenylisocyanate to obtain chiral chromatographic fixed phase stuffing. The silicon gel carrier is first reacted with 3-aminopropyl triethoxy silane for silanation and then space arm activated; and the activated silicon gel carrier is bonded with vancomycin and finally derivated with phenylisocyanate. The chiral chromatographic fixed phase stuffing of vancomycin phenylisocyanate after assembled to column may be used in forward phase, reverse phase and polar organic phase chromatographic condition. The present invention may be used in simple polar organic phase mode to resolve the medicine antimer of zolmitriptan, lamivudine, etc.

The invention provides powder formulations containing zolmitriptan, or a pharmaceutically acceptable salt thereof, which are useful for pulmonary administration to the respiratory tract of a patient for the treatment of disease.

Silicon dioxide free orally disintegrating tablet formulations of zolmitriptan or a pharmaceutically acceptable salt thereof having magnesium carbonate heavy and sodium stearyl fumarate with one or more pharmaceutically acceptable excipients and a process for preparing such a formulation and its use in the treatment of migraines.

Crystalline polymorphic forms of zolmitriptan, solid amorphous zolmitriptan, and processes for preparing them.

The invention relates to a method for preparing Zolmitriptan, which comprises the following steps: (1) obtaining a mixed solution containing (S)-4-(4-hydrazinobenzyl)-2-oxazolidinone by sequentially conducting diazotization reaction, reduction reaction and hydrolysis reaction on (S)-4-(4- aminobenzyl)-2-oxazolidinone; and (2) leading the (S)-4-(4-hydrazinobenzyl)-2-oxazolidinone in the mixed solution obtained in the step (1) and the dimethylamine butyral to carry out fisher-indole reaction so as to generate the Zolmitriptan, wherein in the step (2), the fisher-indole reaction is kept under the condition with the pH of 3-5. Compared with the prior art, the preparation method has the advantages that the molar yield is improved to 55%, the production cost of the Zolmitriptan is low and the preparation method is more applicable to industrial production.

The present invention relates to an improved process for the preparation of the active pharmaceutical ingredient zolmitriptan. In particular, it relates to an efficient process for the preparation of zolmitriptan and its pharmaceutically acceptable salts and solvates.

In the preparation of zolmitriptan of formula III the reduction of the diazonium salt to (5)-4-(4-hydrazinobenzyl)-1,3-oxazolidin-2-one of formula IV is performed in a more concentrated mixture and by the effect on an alkali metal disulphite, preferably sodium disulphite. A zolmitriptan toluene solvate, characterized by a toluene content of 9 to 14% by weight according to the gas chromatography determination and by a maximum of the corresponding mass loss at temperatures of about 111° C. in the gravimetric analysis record. A zolmitriptan toluene solvate, showing strong Raman bands at the wave numbers of 1443 and 1354 cm⁻1, characteristic for the crystal lattice of zolmitriptan with built-in toluene, and further marked bands at 1004 and 786 cm⁻1, characteristic for toluene.

The invention belongs to the technical field of organic synthesis, and in particular relates to a preparation method of a zolmitriptan intermediate. (S)-4-(4-nitrobenzyl)-2-oxazolidinone used as a rawmaterial reacts with palladium-carbon and ammonium formate to prepare the zolmitriptan intermediate (S)-4-(4-aminobenzyl)-2-oxazolidinone. The method adopting the ammonium formate and palladium-carbon to carry out reduction has the advantages of low reaction temperature, simplicity in post-treatment, environmental friendliness, and recycling of a catalyst. The method allows the yield to reach 95%or more and the purity to reach 98% or more.

The present invention provides a convenient and industrially viable process for preparation of Zolmitriptan (I) having desired purity. The invention specifically relates to a method for isolating (S)-4-(4-hydrazinobenzyl)-1,3-oxazolidin-2-one hydrochloride (IIIa) of desired purity by separating the undesired inorganic side products such as stannous hydroxide by manipulation of pH at different stages and finally treating with N,N-dimethylamino butyraldehyde diethyl acetal in an acidic medium to provide Zolmitriptan (I) conforming to regulatory specifications.

An enantioselective process for preparing zolmitriptan, (S)-4-{[3-[2-(dimethylamine)ethyl]-1H-indol-5-yl]methyl}-2-oxazolidinone), by asymmetric hydrogenation of (Z)-2-(acetylamino)-3-{[3-N,N-(dimethylamine)ethyl)-1H-indol-5-yl]-2-propenoic acid methyl ester in the presence of hydrogen and an enantioselective chiral phosphine transition metal catalyst.